REG - Abbott Laboratories - Abbott Reports 2Qtr 2014 Earnings Results <Origin Href="QuoteRef">ABT.N</Origin> - Part 2
- Part 2: For the preceding part double click ID:nRSP5029Ma
43 49 (14.2)
Net foreign exchange (gain) loss 3 40 (92.0)
Other (income) expense, net 6 (2) n/m
Earnings from Continuing Operations before taxes 1,160 1,155 0.4
Taxes on Earnings from Continuing Operations 361 134 n/m 1)
Earnings from Continuing Operations 799 1,021 (21.7)
Earnings from Discontinued Operations, net of taxes 42 -- n/m 2)
Net Earnings $841 $1,021 (17.6)
Net Earnings from Continuing Operations, excluding
Specified Items, as described below $1,470 $1,399 5.1 3)
Diluted Earnings per Common Share from Continuing Operations $0.52 $0.64 (18.8)
Diluted Earnings per Common Share from Discontinued Operations 0.03 -- n/m
Diluted Earnings per Common Share $0.55 $0.64 (14.1)
Diluted Earnings per Common Share from Continuing
Operations, excluding Specified Items, as described below $0.95 $0.88 8.0 3)
Average Number of Common Shares Outstanding
Plus Dilutive Common Stock Options and Awards 1,532 1,582
1) Increase over prior year is a result of specified items, including non-recurring 2013 benefits of U.S. tax law changes enacted in 2013 related to 2012 results, and 2014 year-to-date tax expense associated with a one-time repatriation of 2014 ex-U.S. earnings, offset by a net favorable adjustment to 2014 tax expense related to the resolution of various tax positions from previous years.
2) 2014 Earnings from Discontinued Operations, net of taxes, includes a net favorable adjustment to tax expense of $42 million, or $0.03 per share, as a result of the resolution of various tax positions from previous years related to AbbVie operations.
3) 2014 Net Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $671 million, or $0.43 per share, for intangible amortization expense, expenses associated with cost reduction initiatives, as well as year-to-date tax expense associated with a one-time repatriation of 2014 ex-U.S. earnings, partially offset by a net favorable adjustment to tax expense related to the resolution
of various tax positions from previous years.
2013 Net Earnings, excluding Specified Items, excludes after-tax charges of $481 million, or $0.31 per share, for intangible amortization expense, cost reduction initiatives and other costs. These items were partially offset by the favorable adjustment to tax expense of $103 million, or $0.07 per share, for the impact of U.S. tax law changes enacted in 2013 related to 2012 results.
NOTES:
b) See tables below for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
Non-GAAP Reconciliation of Financial Information
Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
Second Quarter Ended June 30, 2014 and 2013
(in millions, except per share data)
(unaudited)
2Q14
As Specified As % to
Reported Items Adjusted Sales
(GAAP)
Intangible Amortization Expense $161 ($161) --
Gross Margin 2,884 188 $3,072 55.3%
R&D 335 (1) 334 6.0%
SG&A 1,788 (96) 1,692 30.5%
Other (Income) Expense, Net 3 (2) 1
Earnings from Continuing Operations before taxes 737 287 1,024
Taxes on Earnings from Continuing Operations 277 (82) 195
Net Earnings from Continuing Operations 460 369 829
Diluted Earnings per Share from Continuing Operations $0.30 $0.24 $0.54
Specified items reflect intangible amortization expense of $161 million and
other expenses, primarily associated with cost reduction initiatives of $126
million, as well as current quarter tax expense of $123 million associated
with a one-time repatriation of 2014 ex-U.S. earnings.
2Q13
As Specified As % to
Reported Items Adjusted Sales
(GAAP)
Intangible Amortization Expense $197 ($197) --
Gross Margin 2,704 291 $2,995 55.0%
R&D 363 (8) 355 6.5%
SG&A 1,714 (17) 1,697 31.2%
Earnings from Continuing Operations before taxes 601 316 917
Taxes on Earnings from Continuing Operations 125 68 193
Net Earnings from Continuing Operations 476 248 724
Diluted Earnings per Share from Continuing Operations $0.30 $0.16 $0.46
Specified items, as previously identified in Abbott's earnings release dated
July 17, 2013, reflect intangible amortization expense of $197 million and
other expenses, primarily associated with cost reduction initiatives of $119
million.
Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
First Half Ended June 30, 2014 and 2013
(in millions, except per share data)
(unaudited)
1H14
As Specified As % to
Reported Items Adjusted Sales
(GAAP)
Intangible Amortization Expense $335 ($335) --
Gross Margin 5,484 418 $5,902 54.7%
R&D 722 (50) 672 6.2%
SG&A 3,550 (182) 3,368 31.2%
Other (Income) Expense, Net 6 (5) 1
Earnings from Continuing Operations before taxes 1,160 655 1,815
Taxes on Earnings from Continuing Operations 361 (16) 345
Net Earnings from Continuing Operations 799 671 1,470
Diluted Earnings per Share from Continuing Operations $0.52 $0.43 $0.95
Specified items reflect intangible amortization expense of $335 million and
other expenses, primarily associated with cost reduction initiatives of $320
million, as well as year-to-date tax expense of $198 million associated with a
one-time repatriation of 2014 ex-U.S. earnings, partially offset by a net
favorable adjustment to tax expense of $58 million related to the resolution
of various tax positions from previous years.
1H13
As Specified As % to
Reported Items Adjusted Sales
(GAAP)
Intangible Amortization Expense $396 ($396) --
Gross Margin 5,451 544 $5,995 55.4%
R&D 709 (5) 704 6.5%
SG&A 3,500 (48) 3,452 31.9%
Net Foreign Exchange (Gain) Loss 40 (15) 25
Other (Income) Expense, Net (2) (3) (5)
Earnings from Continuing Operations before taxes 1,155 615 1,770
Taxes on Earnings from Continuing Operations 134 237 371
Net Earnings from Continuing Operations 1,021 378 1,399
Diluted Earnings per Share from Continuing Operations $0.64 $0.24 $0.88
Specified items, as previously identified in Abbott's earnings release dated
July 17, 2013, reflect intangible amortization expense of $396 million and
other expenses, primarily associated with cost reduction initiatives of $219
million, as well as a favorable tax expense adjustment of $103 million for the
impact of U.S. tax law changes enacted in 2013 related to 2012 results.
Tax Rate Reconciliation
A reconciliation of the second-quarter tax rates for 2014 and 2013 is shown
below:
2Q14
(dollars in millions) Pre-Tax Income 1) Taxes on Earnings Tax
Rate
As reported (GAAP) $737 $277 37.6%
Specified items 287 (82) 2)
Excluding specified items $1,024 $195 19.0%
2Q13
(dollars in millions) Pre-Tax Income 1) Taxes on Earnings Tax
Rate
As reported (GAAP) $601 $125 20.8%
Specified items 316 68
Excluding specified items $917 $193 21.0%
1) Earnings from Continuing Operations before income taxes.
2) Specified items include current quarter tax expense of $123 million associated with a one-time repatriation of 2014 ex-U.S. earnings.
A reconciliation of the year-to-date tax rates for 2014 and 2013 is shown
below:
1H14
(dollars in millions) Pre-Tax Income 3) Taxes on Earnings Tax
Rate
As reported (GAAP) $1,160 $361 31.1%
Specified items 655 (16) 4)
Excluding specified items $1,815 $345 19.0%
1H13
(dollars in millions) Pre-Tax Income 3) Taxes on Earnings Tax
Rate
As reported (GAAP) $1,155 $134 11.6%
Specified items 615 237 5)
Excluding specified items $1,770 $371 21.0%
3) Earnings from Continuing Operations before income taxes.
4) Specified items include year-to-date tax expense of $198 million associated with a one-time repatriation of 2014 ex-U.S. earnings, partially offset by a net favorable adjustment to tax expense of $58 million related to the resolution of various tax positions from previous years.
5) Specified items include a favorable adjustment to tax expense of $103 million for the impact of U.S. tax law changes enacted in 2013 related to 2012 results.
CONTACT: Financial, Brian Yoor, (847) 937-6343, or Tina Ventura, (847)
935-9390, or Scott Leinenweber, (847) 935-1898; Media, Scott Stoffel, (847)
936-9502, or Angela Duff, (847) 938-6894
This information is provided by RNS
The company news service from the London Stock ExchangeRecent news on Abbott Laboratories
See all newsREG - Takeover Panel - Disclosure Table
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG - Takeover Panel - Disclosure Table
Announcement